within Pharmacolibrary.Drugs.ATC.J;

model J02AX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.005166666666666667,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.0346,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Rezafungin acetate is an echinocandin antifungal agent indicated for the treatment of candidemia and invasive candidiasis. It acts by inhibiting the synthesis of Î²-(1,3)-D-glucan, an essential component of the fungal cell wall. Rezafungin was approved by the FDA in 2023 for clinical use in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult healthy volunteers and patients with candidemia or invasive candidiasis after intravenous infusion.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J02AX08;
